LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

Allogene Therapeutics Inc

Затворен

СекторЗдравеопазване

1.22 -5.43

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.21

Максимум

1.23

Ключови измерители

By Trading Economics

Приходи

206K

-60M

EPS

-0.28

Марж на печалбата

272,450

Служители

226

EBITDA

-302K

-56M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+613.82% upside

Дивиденти

By Dow Jones

Следващи печалби

6.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

44M

300M

Предишно отваряне

6.65

Предишно затваряне

1.22

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Allogene Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.06.2025 г., 18:52 ч. UTC

Печалби

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

22.06.2025 г., 23:56 ч. UTC

Печалби

Renesas Electronics: May Book Y250B Loss Related to Wolfspeed Restructuring in 1H

22.06.2025 г., 23:55 ч. UTC

Пазарно говорене

Markets Wait to See if Iran's Response Will be Symbolic or Substantial -- Market Talk

22.06.2025 г., 23:51 ч. UTC

Пазарно говорене

Oil Climbs After U.S. Attack on Iran's Nuclear Sites -- Market Talk

22.06.2025 г., 23:43 ч. UTC

Пазарно говорене

Reasons to Believe Strait of Hormuz Will Remain Open -- Market Talk

22.06.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Fall as Middle East Uncertainty Persists -- Market Talk

22.06.2025 г., 23:11 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.06.2025 г., 23:11 ч. UTC

Пазарно говорене

Early Market Reaction to Iran Attacks Restrained -- Market Talk

22.06.2025 г., 22:59 ч. UTC

Пазарно говорене

Gold, Silver Rise as Investors Seek Haven After Strikes on Iran -- Market Talk

22.06.2025 г., 21:43 ч. UTC

Пазарно говорене

Australian Govt Says Supports US Strikes On Iran -- Market Talk

21.06.2025 г., 08:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

21.06.2025 г., 08:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

21.06.2025 г., 08:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.06.2025 г., 20:13 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20.06.2025 г., 20:11 ч. UTC

Пазарно говорене

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20.06.2025 г., 19:56 ч. UTC

Пазарно говорене

Crude Oil Slips to End Week -- Market Talk

20.06.2025 г., 18:35 ч. UTC

Пазарно говорене

Warehouse Clubs Seen Growing Market Share -- Market Talk

20.06.2025 г., 18:12 ч. UTC

Пазарно говорене

Gold Slides to Close Shortened Week -- Market Talk

20.06.2025 г., 17:56 ч. UTC

Пазарно говорене

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20.06.2025 г., 17:50 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20.06.2025 г., 17:35 ч. UTC

Придобивния, сливания и поглъщания

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20.06.2025 г., 17:30 ч. UTC

Пазарно говорене
Печалби

Adobe's AI Headwinds Seen Fading -- Market Talk

20.06.2025 г., 17:03 ч. UTC

Печалби

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20.06.2025 г., 16:50 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

20.06.2025 г., 16:50 ч. UTC

Пазарно говорене
Печалби

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20.06.2025 г., 16:44 ч. UTC

Придобивния, сливания и поглъщания

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20.06.2025 г., 16:40 ч. UTC

Пазарно говорене
Печалби

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Allogene Therapeutics Inc Прогноза

Ценова цел

By TipRanks

613.82% нагоре

12-месечна прогноза

Среден 8.78 USD  613.82%

Висок 14 USD

Нисък 4 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Allogene Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

11

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

1.18 / 1.69Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.